lasmiditan

FDA Drug Profile — Reyvow

lasmiditan is listed in the FDA National Drug Code directory with 8 NDC codes, marketed under brand name including Reyvow. Available dosage form: tablet.

Drug details

Generic Name
lasmiditan
Brand Names
Reyvow
Application Number
NDA211280
Sponsor
Lilly Del Caribe, Inc.
NDC Codes
8
Dosage Forms
TABLET
Routes
ORAL
Active Ingredients
LASMIDITAN

Indications and Usage

1 INDICATIONS AND USAGE REYVOW ® is indicated for the acute treatment of migraine with or without aura in adults. REYVOW ® is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use REYVOW is not indicated for the preventive treatment of migraine. ( 1 ) Limitations of Use REYVOW is not indicated for the preventive treatment of migraine.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.